Mikołaj Kocikowski
Mikołaj Kocikowski
Bioinformatics | Cancer Immunology | Antibody Science | Comparative Oncology
About
15
Publications
3,371
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
66
Citations
Introduction
Additional affiliations
April 2017 - October 2017
Polpharma Biologics
Position
- Quality Assurance Specialist
February 2016 - April 2017
Polpharma Biologics
Position
- R&D Associate
Publications
Publications (15)
Promiscuity in T-cell antigen landscapes refers to the dual flexibility of peptides binding multiple MHC alleles and MHC alleles presenting diverse arrays of peptides. By understanding how neoantigens are shared across varied HLA backgrounds, promiscuity analysis can inform the selection of cancer-vaccine targets that reach a wider segment of the p...
Background
Addressing the poor prognosis associated with esophageal adenocarcinoma (EAC) has been hindered by the absence of biomarkers for early disease detection and therapeutic targets. Despite extensive research on the somatic mutations associated with EAC, the impact of genomic aberrations on protein expression and cancer phenotype remains unc...
In the quest for improved therapeutics targeting immune checkpoints (ICs), we turn to spontaneously developing dog (canine) cancers, which are unique models that genetically and clinically mirror human equivalents. Despite its potential, canine cancer immunology remains largely unexplored. Here, we examine the RNA-seq-based expression of 44 ICs acr...
Monoclonal antibodies targeting immune checkpoints have revolutionized oncology. Yet, the effectiveness of these treatments varies significantly among patients, and they are associated with unexpected adverse events, including hyperprogression. The murine research model used in drug development fails to recapitulate both the functional human immune...
Efforts to address the poor prognosis associated with esophageal adenocarcinoma (EAC) have been hampered by a lack of biomarkers to identify early disease and therapeutic targets. Despite extensive efforts to understand the somatic mutations associated with EAC over the past decade, a gap remains in understanding how the atlas of genomic aberration...
Canine apocrine gland anal sac adenocarcinoma (AGASACA) is an aggressive canine tumor originating from the anal sac glands. Surgical resection, with or without adjuvant chemotherapy, represents the standard of care for this tumor, but the outcome is generally poor, particularly for tumors diagnosed at an advanced stage. For this reason, novel treat...
Background: Efforts to address the poor prognosis associated with esophageal adenocarcinoma (EAC) have been hampered by a lack of biomarkers to identify early disease and therapeutic targets. Despite extensive efforts to understand the somatic mutations associated with EAC over the past decade, a gap remains in understanding how the atlas of genomi...
Over the past few years, many molecules such as monoclonal antibodies, affibodies, nanobodies, and small compounds have been designed and tested as inhibitors of PD-1/PD-L1 complex formation. Some of them have been successfully implemented into clinical oncology practice. However, the majority of these compounds have disadvantages and limitations,...
A comparative canine-human therapeutics model is being developed in B-cell lymphoma through the generation of a hybridoma cell that produces a murine monoclonal antibody specific for canine CD20. The hybridoma cell produces two light chains, light chain-3, and light chain-7. However, the contribution of either light chain to the authentic full-leng...
Immune blockade of inhibitory immune checkpoint (IC) mediated by Programmed cell death protein 1 (PD1) significantly increases survival of patients with advanced melanoma and other cancers. Dogs constitute a unique model for studying cancer types relevant to humans. Canine malignancies occur spontaneously and share many pathogenic pathways as well...
There is limited advancement in osteosarcoma therapy in humans. Interestingly, dogs spontaneously develop very similar disease at higher frequency, making canines a perfect model to study OS. Recent introduction of immune checkpoint blockade has revolutionized cancer therapy. Despite huge success, immunotherapy is still not effective in some group...
Immune evasion is a major challenge for the development of successful cancer treatments. One of the known mechanisms is the expression of immune checkpoints (ICs)—proteins regulating the immune cells activation. The advent of immunotherapy using monoclonal antibodies (mAbs) to block the immune checkpoint receptor-ligand interaction brought about a...
Solitary aculeate wasps are abundant and diverse hymenopteran insects that disable prey using venom. The venom may possess neuromodulation, immunomodulatory, metabolic-modulatory and antimicrobial functions. Venom analysis using transcriptome or mass spectrometry has been previously performed in social and parasitoid wasp species. We develop method...
Urothelial carcinoma (UC) is the fourth most common malignancy in human and the most common form of urinary bladder cancer in dogs. This neoplasia tends to be invasive at advanced stages hence novel therapeutic approaches are urgently needed. As urothelial carcinomas share many similarities between the dog and human in the immunological responses,...
Questions
Questions (2)
Hi, I am wondering whether anyone else has problems with this kit from Promega?
The issue is a huge variation between replicates in this assay, the standard deviation and %CV being unacceptable every time. Our whole team tried to use or optimize throughout 3 years and the results are still unusable. So many boxes of the reagent wasted.
To be clear, the issue happens despite changing: the operator, the lab, the plate reader, reagents batches, cell line/PBMC source, cell density, incubation time, using cell strainers... It is also not a well effect or well (luminescent) cross-talk and we do not use the wells on the plate perimeter for the tested samples.
I tried to ask Promega for troubleshooting advice but they ignored the emails. Obviously we neither rely on nor recommend this kit anymore, but I'd like to solve this mystery. Do you also have this issue or can suggest any ways to improve the result consistency?
Thanks for your time!
Hello,
Can one compare binding (curve, EC50...) of 2 antibodies by ELISA if they require different detection secondary mAbs? Both have the same variable domain and hence the same target but the constant chains are from two different species. I do understand assays such as SPR would be more appropriate but can anything be concluded from an early comparison by ELISA?
Many thanks any thoughts!
